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In the present study, the role of endothelin-1 (ET-1) on alter-
ations of hepatic and renal metallothionein (MT) and trace met-
als (Zn, Cu, and Fe) were investigated in streptozotocin (STZ)-
induceddiabeticrats.Diabeticrats,age-andsex-matchedcontrols,
aswellascontrolanddiabeticanimalsonadualETA/ETB receptor
blocker, bosentan, were investigated after 6 months of follow-up.
MTwasmeasuredbycadmium-hemeassay.Metalsweremeasured
by atomic absorption spectrometer. ET-1 mRNA was analyzed by
reverse transcriptase–polymerase chain reaction (RT-PCR) tech-
nique. Hepatic and renal ET-1 mRNA was increased in diabetic
rats as compared to control rats, along with an increase in both
hepatic and renal MT proteins. The increased hepatic MT protein
level was associated with decreases in hepatic Cu and Fe, whereas
increased renal MT was associated with increases in renal Cu and
Fe accumulation. Zn levels were unaltered in both organs in dia-
betic rats. Bosentan treatment partially prevented the increase in
MT levels in both liver and kidney, along with reduced serum cre-
atinine and increased urinary creatinine levels. Further bosentan
treatment corrected the increased Cu and Fe levels in the kidney in
diabetic rats, but reduced hepatic Cu and Fe levels. No signiﬁcant
effects of bosentan treatment on nondiabetic rats were observed.
The data suggest that the possible effects of ET antagonism in dia-
betes may be mediated via changes in MT and trace metals.
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In diabetic patients, the deranged regulation of hemodynam-
ics may occur in a variety of organs [1, 2]. Vasoactive factors
that are perturbed under hyperglycemic conditions may lead to
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altered tissue hemodynamics. A group of vasoactive proteins
called endothelins (ETs) have been implicated in the pathogen-
esis of diabetes-induced vascular dysfunction in various organs
[3–5]. ETs are a family of 21–amino acid peptides that include
ET-1, ET-2, and ET-3, and interact in mammals with a group
of receptors namely, ETA and ETB [6, 7]. ETs, originally dis-
covered as endothelial products, have since been found in other
organs, including liver and kidney [6–8]. ETs and their recep-
tors were found to be altered in various target organs of diabetic
complications in rats, suggesting the possible involvement of
ETs in the pathogenesis of diabetic complications [3–5, 9, 10].
Along with their important roles in modulation of tissue blood
ﬂow, ET-1 is also able to stimulate cell proliferation by acting
as a mitogenic factor [6, 7].
We have previously demonstrated that high glucose–induced
augmentation of ET-1 expression in endothelial cells may reg-
ulate the expression of other stress-responsive proteins such as
metallothionein (MT) [11]. MTs are a group of low-molecular-
weight(6000to7000Da),cysteine-rich(30%)intracellularpro-
teins with high afﬁnity for zinc (Zn) and copper (Cu). Four ma-
jor isoforms of MT have been identiﬁed in mammalian tissues;
MT-I and MT-II isoforms being the 2 major isoforms found in
most tissues. Several physiologic roles have been proposed for
MT, including detoxiﬁcation of potentially toxic metals such as
cadmium (Cd) and storage of essential metals such as zinc and
copper [12, 13]. MT is induced readily in the liver by a variety
of factors such as glucocorticoids, bacterial lipopolysaccharide
(LPS), interferon, alkylating agents, and radiation [12–14]. MT,
in addition, as one of the stress-responsive proteins, can be in-
duced by a variety of cytokines, such as interleukin-1 (IL-1),
interleukin-6 (IL-6), and tumour necrosis factor-® (TNF®), dur-
ingimmunologicalorinﬂammatoryreactionsandmaytherefore
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be of importance in several disease processes [12–15]. MT lev-
els are also increased in response to chronic stresses such as
allogenic and isogenic organ transplantation [16, 17]. There are
a few reports on increased levels of MT in kidney and liver of
diabetic rats [18–20].
The aim of the present study was to investigate whether,
similar to our previous ﬁndings in endothelial cells, chronic
diabetes affects MT expression in the liver and kidney by an
ET-dependent pathway, and if such an alteration may modulate
trace metal accumulation in these organs.
MATERIALS AND METHODS
Animals and Treatments
All animals were cared for in accordance with the University
of Western Ontario Council on Animal Care Committee, who
formally approved all experimental protocols. Male Sprague-
Dawleyratsofapproximately200gwereobtainedfromCharles
RiverCanada(St.Constant,PQ,Canada)andweregivenregular
rat chow and water ad libitum. The rats were randomly divided
into 4 groups: namely, nondiabetic control rats (C), diabetic
rats (D), diabetic rats treated with bosentan (DB), and nondia-
beticcontrolratstreatedwithbosentan(CB).Bosentan,apotent
orallyactivedualETA/ETB receptorblocker,wasobtainedfrom
Actelion (Allschwill, Switzerland, courtesy of Dr. M. Clozel)
[21].
Diabetes was induced with a single intravenous injection of
streptozotocin (STZ, 65 mg/kg body weight in citrate buffer;
Sigma, St. Louis, MO). The control animals received the same
volume of buffer injection alone. Diabetic animals were moni-
toreddailywithrespecttourinevolume,sugar,andketones,and
received a daily dose of insulin (»2 U/day) to prevent ketosis.
Body weight and blood glucose levels were monitored regu-
larly. Bosentan was administered by daily oral gavage at the
dose of 100 mg/kg body weight/day. Animals from each group
were sacriﬁced after 6 months of follow-up. Urine and serum
creatinine levels were measured in the urine and blood samples
collected at the time of sacriﬁce. The animals were anesthetized
with sodium pentobarbital (50 mg/kg, intraperitoneal [IP]) and
were sacriﬁced by cardiac puncture. Liver and kidney tissues
were removed. Part of the right lobe of the liver and right renal
cortex from each animal were snap frozen in liquid nitrogen and
were stored at ¡80±C until analysis of mRNA. The remaining
portion of the right lobe of liver and right renal cortex were
frozen and used for analysis of MT protein and metal levels.
MT Measurement by Cadmium-Hemoglobin
Assay
MT levels in hepatic and renal tissues were determined by a
cadmium-hemoglobin (Cd-heme) assay as previously described
by us [22]. Brieﬂy, the dissected tissues were homogenized in
0.25 M sucrose and centrifuged at 20,000 rpm for 20 min-
utes. An aliquot of the resulting supernatant fraction, diluted
with 30 mM Tris-HCl buffer (pH 8.0), was incubated with
10 ppm 109Cd solution with known speciﬁc activity to satu-
rate the metal-binding sites of MT. Excess Cd was removed by
addition of rat hemolysate to the assay tubes followed by heat
treatment in a boiling water bath, which caused precipitation
of Cd-heme and other proteins, except MT (which is heat sta-
ble). The denatured proteins were removed by centrifugation
at 10,000 rpm for 2 minutes. Hemolysate treatment/heat de-
naturation/centrifugation steps were repeated 3 times. The Cd
concentrations in the ﬁnal supernatant were calculated from the
radioactivity of the 109Cd, which was measured by a ° counter
(1272Clinigamma,LKBWallac;Turku,Finland),andwascon-
verted to MT concentration on the basis of 7 g-atoms of cad-
mium/MT. The total hepatic and renal MT concentrations were
expressed as micrograms per gram of wet tissue.
Metal Quantiﬁcation
Zn,Cu,andFeconcentrationsofliverandkidneysweredeter-
mined by an atomic absorption spectrometry (Varian Spectra-
AA 30, Georgetown, Ontario, Canada) using an air-acetylene
ﬂame after tissue digestion, as previously described by us [22].
Preweighed pieces of tissue samples were digested in nitric acid
atroomtemperatureovernightandthenheatedto95±Cfor1hour
to facilitate digestion. The resulting clear liquid was used for
analysis. Zn, Cu, and Fe concentrations were expressed as mi-
crograms per gram wet tissue.
ET-1 mRNA Measurement
TRIZOL reagent (Canadian Life Technologies, Burlington,
Ontario,Canada)wasusedtoisolateRNAfromthetissuesasde-
scribedbymanufacturer’sinstruction.QuantitationofRNAwas
performedbydeterminingtheabsorbanceat260nmand280nm.
FirststrandcDNAsynthesiswasperformedusingSuperscript-II
system (Canadian Life Technologies) as previously described
[3]. The ampliﬁcation was carried out using our previously de-
scribedmethodologies[3].TheET-1primers,50-GCTCCTGCT
CCT CCT TGA TG-30 (sense) and 50-CTC GCT CTA TGT
AAG TCA TGG-30 (antisense), with a predicted product size
of 499 bp, were used. Reactions were performed in 30-¹l vol-
umes containing 1£ polymerase chain reaction (PCR) buffer,
1.5 mM MgCl2, 250 ¹M dNTP mix, 1 ¹M of each ampliﬁca-
tion primer, 2.5 U Taq polymerase, and 4 ¹l of the reverse tran-
scriptase (RT) product. The initial cycle was carried out using
3 minute at 94±C for denaturation, 1 minute at 60±C for anneal-
ing, and 3 minutes at 72±C for extension. Subsequent cycles of
PCR were performed using the following conditions: denatura-
tion, 45 seconds at 94±C; annealing, 45 seconds at 54±C; andET-1–MEDIATED ALTERATION OF MT AND TRACE METALS 195
extension, 1 minute at 72±C; and 7 minutes for ﬁnal extension.
The linearity of the PCR reaction was established by analyzing
the PCR product with variable amount of template and vari-
able cycle numbers. It has been previously shown that in this
reaction the PCR ampliﬁcation is log-linear up to 40 cycles. In
this study, we used 30 cycles of ampliﬁcation. Simultaneously
a housekeeping gene (¯-actin) was ampliﬁed in a separate set
of tubes using the same RT product. The primer sequences for
¯-actin are 50-TGG TGG TAT GGG TCA GAA GG-30 (sense)
and 50-ATC CTG TCA GCG ATG CCT GGG-30 (antisense),
with a predicted product size of 813 bp. The ampliﬁcation prod-
uctswereanalyzedona2.5%agarosegel,stainedwithethidium
bromide, and visualized under ultraviolet (UV) light. Quanti-
tation was performed by serial dilution slot-blot hybridization
and densitometry of the products from the upstream of ampli-
ﬁcation onto the nylon membranes. Hybridizations were per-
formed with biotinylated ampliﬁcation product speciﬁc oligo-
probes (ET-1: 50-CAA AGA CCA CAG ACC AAG GG-30 and
¯-actin: 50-CTG ACC CTG AAG TAC CCC ATT-30) [3]. The
detection was carried out using a NBT/BCIP system (Sure Blot,
Oncor, Gathisburg, MD, USA). The blots were analyzed by a
Hewlett-Packard 4C scanner and Mocha Image Analysis Soft-
ware (Jandel Scientiﬁc, San Rapael, CA, USA). Each sample
was analyzed in duplicate. The densitometric values were ex-
pressed in arbitrary units per microgram of total RNA and
the ratio of ¯-actin to ET-1 was obtained as previously des-
cribed [3].
Statistical Analysis
Data are expressed as mean § SE, with a minimum of 5
rats per group. The data were subject to unpaired 2-tail Stu-
dent’s t test. A P value of 0.05 or less was accepted as being
signiﬁcant.
RESULTS
Clinical Parameters
Diabetic rats showed glucosuria (>2%), hyperglycemia, and
reduced body weight, compared to the age- and sex-matched
controlanimals(datanotshown).Bosentantreatmenthadnoef-
fect on these parameters. Diabetic animals showed increased
serum creatinine levels (D: 5.6§0.8 mg/dl versus C: 4.0§
0.5 mg/dl, P<0.05), which were corrected by bosentan treat-
ment (DB: 3.3§0.6 mg/dl, P <0.05).
MT Protein and Metal Alterations
in Diabetic Rats
Hepatic as well as renal MT proteins were signiﬁcantly in-
creasedinSTZ-diabeticratsat6monthsafterdiabetes(Figure1).
FIGURE 1
MT protein levels in livers and kidneys of control (C), diabetic
(D), bosentan-treated diabetic (DB), and bosentan-treated
control rats (CB) after 6 months of follow-up. Data are
presented as mean § SE, nD6 in all groups. *Signiﬁcantly
different from C; **signiﬁcantly different from C and DB.
The hepatic Zn, Cu, and Fe levels were signiﬁcantly
(P<0.05) decreased in the diabetic rats at 6 months (Figure 2).
In contrast, renal Cu and Fe levels were increased (P<0.05) in
diabetic rats, with no change in renal Zn levels (Figure 2).
FIGURE 2
Zn, Fe, and Cu levels in livers and kidneys of control (C),
diabetic (D), bosentan-treated diabetic (DB), and
bosentan-treated control rats (CB) after 6 months of follow-up.
Data are presented as mean § SE, nD6 in all groups.
*Signiﬁcantly different from C; **signiﬁcantly different from
C and DB.196 L. CAI ET AL.
FIGURE 3
mRNA analysis of ET-1 by semiquantitative RT-PCR from
livers and kidneys of control (C), diabetic (D), bosentan-treated
diabetic (DB), and bosentan-treated control rats (CB) after
6 months of follow-up. Data are expressed as the ratio of ET-1
gene to housekeeping gene, ¯-actin. Lower panel shows
representative gel pictures. *Signiﬁcantly different from C.
ET-1 mRNA Expression in Diabetic Rats
Compared to the nondiabetic control animals, diabetic rats
showed increased expression of ET-1 mRNA in the liver and
kidney (Figure 3). As there are no intracellular storage mech-
anism for ET-1, the changes in mRNA levels are reﬂective of
protein levels [6, 7]. Bosentan treatment had no effect on ET-1
mRNA expression in diabetic or control rats.
Effects of Bosentan on MT and Metal Alterations
Intheliver,increasedMTproteinindiabeticratswasnotpre-
ventedbytheadministrationofbosentan(Figure1).ETreceptor
blockadewithbosentantendedtorestorethereducedZnlevelsin
theliverofdiabeticrats.However,withrespecttohepaticCuand
Fe, it further aggravated the diabetes-induced reduction of these
2metals(Figure2).Incontrast,inthekidneys,althoughbosentan
tended to decrease MT protein levels (Figure 1), it completely
restored the diabetes-induced increases in Cu and Fe levels. No
effect of bosentan on renal Zn levels were seen (Figure 2). No
effects of bosentan treatment on MT or metal levels were noted
in control animals in any of the organs studied.
DISCUSSION
Hyperglycemia may trigger several alterations in metabolic
events,includingtheabnormalmetabolismoftraceelementsand
relatedproteinsinvariousorgans[18–20].Inthisstudy,wehave
demonstrated that alterations in metal-binding proteins, in both
the kidney and liver, at least in part, may be regulated via ETs.
However,thepatternofassociatedeffectsonmetalaccumulation
varied in these 2 organs; in contrast to reduced Cu and Fe levels
in the liver, the kidney showed increased levels. Some of these
changes were corrected by ET antagonism with bosentan.
These ﬁndings demonstrate a novel mechanism of regula-
tion of metal-binding proteins and metal distribution in diabetic
animals. These data are in keeping with our previous ﬁndings
in endothelial cells, which showed that high glucose increases
both MT mRNA and protein expression and that these changes
are regulated by an ET-dependent pathway [11]. Although other
investigators have demonstrated that ET-1 induces MT expres-
sioninendothelialcellsundernormalglucosecultureconditions
[23], in this study, no effects of ET antagonism on MT levels or
metal accumulation were seen in control rats.
Although the liver showed increased MT expression in dia-
betic rats, this was associated with decreased total hepatic Zn,
Cu, and Fe levels. These ﬁndings are in keeping with previous
studiesandisprobablyrelatedtodecreasedabsorptionofmetals
such as Zn, Cu, and Fe from intestinal mucosa in diabetic rats
[19]. However, the increase in MT suggests that the most of Zn
and Cu may be bound to MT.
In contrast, increased renal MT was accompanied by in-
creased accumulation of renal Cu and Fe. Similar results have
been reported in STZ-diabetic rats [19]. Bosentan completely
prevented the increase in renal Cu and Fe in diabetic rats, and
reduced renal MT protein. Because Zn levels were not altered,
these changes may not be related to food intake.
Although the biological functions of MTs remain elusive,
there are several lines of evidence to suggest important roles for
thisproteininvariousdiseaseconditions,andcouldberelatedto
its effects on homeostasis of metals, apoptosis, and modulation
of nitric oxide (NO) activity [24, 25]. MT may regulate NO sig-
naling in endothelial cells [26, 27]. On the other hand, there is a
feedback regulatory mechanism of NO or ET [28, 29]. Hence,
one may speculate that a regulatory mechanism exists, with in-
teractions among NO, ET, and MT, which targets vascular func-
tions in diabetes. However, further conﬁrmation is needed.
Increased renal Cu levels in chronic diabetes, as shown in
this study, is in keeping with previous data [19, 20]. The exact
signiﬁcance of this ﬁnding is unclear. It is not known whether
increased glomerular ﬁltration in diabetes may in any way con-
tribute to trace metal alteration. It has, however, been postu-
lated that increased Cu in the kidney may effect the activity of
the copper lysyl oxidase enzyme, which is a signiﬁcant compo-
nent in the regulation of basement membrane turnover [30]. It
is of interest to note that recent data demonstrate that there is a
duration-dependentalterationintheCu/ZnratioinSTZ-diabetic
rats, and that increased Cu/Zn ratio in diabetic patients is asso-
ciated with an increased incidence of vascular complicationsET-1–MEDIATED ALTERATION OF MT AND TRACE METALS 197
[31, 32]. Increased Cu has been associated with cardiovascular
disease in patients with end-stage renal failure [33]. Further-
more, increased Cu has been shown to augment the formation
of advanced glycosylation end products and act as an inhibitor
to aminoguanidine [34]. We and others have previously demon-
stratedthatETsareofimportanceinthepathogenesisofdiabetic
nephropathybymodulatinggrowthfactorsandextracellularma-
trix protein production [10, 35]. The effect of ET antagonism on
the serum creatinine levels in the diabetic rats is in keeping with
these observations. The present data suggest that one mecha-
nism of ET blockade in the kidney may be mediated by changes
in trace metals.
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